Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
or

Theravance Bio Ord (TBPH)

Theravance Bio Ord (TBPH)
9.00 x 3 9.73 x 1
Post-market by (Cboe BZX)
9.31 -0.08 (-0.85%) 03/25/25 [NASDAQ]
9.00 x 3 9.73 x 1
Post-market 9.31 unch (unch) 16:02 ET
Quote Overview for Tue, Mar 25th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
9.30
Day High
9.44
Open 9.38
Previous Close 9.39 9.39
Volume 143,300 143,300
Avg Vol 276,450 276,450
Stochastic %K 36.82% 36.82%
Weighted Alpha +3.13 +3.13
5-Day Change +0.10 (+1.09%) +0.10 (+1.09%)
52-Week Range 7.44 - 10.90 7.44 - 10.90
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 464,533
  • Shares Outstanding, K 49,471
  • Annual Sales, $ 64,380 K
  • Annual Income, $ -56,420 K
  • EBIT $ -47 M
  • EBITDA $ -48 M
  • 60-Month Beta 0.15
  • Price/Sales 7.22
  • Price/Cash Flow N/A
  • Price/Book 2.63

Options Overview Details

View History
  • Implied Volatility 82.07% ( -17.24%)
  • Historical Volatility 35.44%
  • IV Percentile 62%
  • IV Rank 45.19%
  • IV High 172.69% on 01/14/25
  • IV Low 7.35% on 10/11/24
  • Put/Call Vol Ratio 0.17
  • Today's Volume 7
  • Volume Avg (30-Day) 5
  • Put/Call OI Ratio 0.49
  • Today's Open Interest 101
  • Open Int (30-Day) 972

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -0.30
  • Number of Estimates 3
  • High Estimate -0.22
  • Low Estimate -0.43
  • Prior Year -0.24
  • Growth Rate Est. (year over year) -25.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
8.90 +4.61%
on 02/26/25
Period Open: 8.97
10.19 -8.64%
on 02/27/25
+0.34 (+3.79%)
since 02/25/25
3-Month
8.35 +11.50%
on 01/16/25
Period Open: 9.85
10.90 -14.59%
on 01/24/25
-0.54 (-5.48%)
since 12/24/24
52-Week
7.44 +25.13%
on 08/09/24
Period Open: 8.76
10.90 -14.59%
on 01/24/25
+0.55 (+6.28%)
since 03/25/24

Most Recent Stories

More News
Zacks Industry Outlook Madrigal, Corcept, Catalyst Larimar and Theravance

For Immediate ReleaseChicago, IL – November 11, 2024 – Today, Zacks Equity Research like Madrigal Pharmaceuticals MDGL, Corcept Therapeutics CORT, Catalyst Pharmaceuticals CPRX, Larimar Therapeutics...

CORT : 58.32 (-1.93%)
TBPH : 9.31 (-0.85%)
MDGL : 343.29 (-0.90%)
LRMR : 2.31 (+1.32%)
CPRX : 25.72 (-0.08%)
5 Small Drug Stocks to Buy as Trump Gets Re-Elected

The drug industry witnessed major policy changes during Joe Biden's four-year term as U.S. President, including the historic Inflation Reduction Act (“IRA”). With Donald Trump’s reelection, the biotech...

CORT : 58.32 (-1.93%)
TBPH : 9.31 (-0.85%)
MDGL : 343.29 (-0.90%)
LRMR : 2.31 (+1.32%)
CPRX : 25.72 (-0.08%)
Theravance Bio: Q4 Earnings Snapshot

Theravance Bio: Q4 Earnings Snapshot

TBPH : 9.31 (-0.85%)
Theravance Bio: Q3 Earnings Snapshot

Theravance Bio: Q3 Earnings Snapshot

TBPH : 9.31 (-0.85%)
Theravance Biopharma to Report Third Quarter 2023 Financial Results on November 7, 2023

/PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will report its third quarter 2023 financial results and provide a business update after market close...

TBPH : 9.31 (-0.85%)
Theravance Biopharma to Participate in an Upcoming Investor Conference

/PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will participate in a Fireside Chat at the H.C. Wainwright 25th Annual Global Investment Conference...

TBPH : 9.31 (-0.85%)
Theravance Biopharma to Present New Ampreloxetine Data at the 2023 International Congress of Parkinson's Disease and Movement Disorders

/PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today announced new ampreloxetine data in neurogenic...

TBPH : 9.31 (-0.85%)
Theravance Bio: Q2 Earnings Snapshot

Theravance Bio: Q2 Earnings Snapshot

TBPH : 9.31 (-0.85%)
Theravance Biopharma, Inc. Reports Second Quarter 2023 Financial Results and Provides Business Update

Q2 2023 YUPELRI® (revefenacin) net sales of $55.0 million, recognized by Viatris, up 12% from Q2 20221 Q2 2023 YUPELRI total retail TRx and new to product TRx...

TBPH : 9.31 (-0.85%)
Theravance Biopharma to Report Second Quarter 2023 Financial Results on August 7, 2023

/PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will report its second quarter 2023 financial results and provide a business update after market...

TBPH : 9.31 (-0.85%)

Business Summary

Theravance Biopharma is a biopharmaceutical company primarily focused on discovering, developing and commercializing respiratory medicines. The company was formed following the split of the erstwhile Theravance into two listed companies in June 2014 - Innoviva, Inc. (then Theravance, Inc.) and Theravance.'...

See More

Key Turning Points

3rd Resistance Point 9.54
2nd Resistance Point 9.49
1st Resistance Point 9.40
Last Price 9.31
1st Support Level 9.26
2nd Support Level 9.21
3rd Support Level 9.12

See More

52-Week High 10.90
Fibonacci 61.8% 9.58
Last Price 9.31
Fibonacci 50% 9.17
Fibonacci 38.2% 8.76
52-Week Low 7.44

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Precision Trading with Bollinger Bands: Identifying Breakouts & Reversals